Winson Y. Cheung, MD, MPH, FRCP(C) is a medical oncologist and a nationally and internationally recognized data scientist and health outcomes researcher who specializes in real-world evidence generation by leveraging big data such as large registries and administrative databases. He is currently a Full Professor of Medicine, Oncology, and Community Health Sciences at the University of Calgary where he is the Director of the Oncology Outcomes (O2) Research Program. Dr. Cheung received his medical degree at the University of British Columbia, medical oncology subspecialty training at the University of Toronto and subsequently obtained a Master of Public Health degree at Harvard University. Before his recruitment to the Calgary Cancer Centre in 2016, he spent the first 6 years of his career at the University of British Columbia where he worked at BC Cancer in his hometown of Vancouver. His clinical expertise focuses on the management of gastrointestinal malignancies, but his research portfolio spans the entire spectrum of cancer from prevention to survivorship across all tumour types. He is the recipient of numerous accolades, including the National Cancer Institute of Canada Dorothy Lamont Award, the Novartis Oncology Young Canadian Investigator Mentor Award, the Multinational Association of Supportive Care in Cancer Investigator Award, and recognitions from the American Society of Clinical Oncology. He has secured 25+ million dollars in grant funding and published over 350 peer-reviewed scientific articles.
Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec and a member of the Centre des maladies du sein. She is a clinical researcher in the oncology axis of the CHU de Québec research center.
She obtained her M.D. from Laval University in 1997 and completed her fellowship in breast cancer at Mount Sinai Hospital in 2005, where she also obtained a Master's degree in clinical epidemiology from the University of Toronto. She has worked at CHU de Québec since 2006. Dr. Lemieux is a member of the Quality of Life and Breast Cancer Committee of the CCTG Clinical Trials Group. She is also on the governance committee of the Quebec breast metastatic registry. Her research activities focus on breast cancer, quality of life, treatment toxicity and use of real life data.
Dr. Ricardo Rendon did his medical school and residency at Universidad Javeriana in Bogota, Colombia. He subsequently completed a clinical and research uro-oncology fellowship at the University of Toronto, Canada and a Master's in Community Health Clinical Epidemiology. He joined Dalhousie University in Halifax, Canada in 2001 where he is a Professor in the Department of Urology and the Director of Research and Clinical Trials and Urologic Oncology. He is the chair of the Genito-Urinary Cancer Site Team at Nova Scotia Health and a senior investigator at the Beatrice Hunter Cancer Research Institute. Dr. Rendon is the immediate past president of the Canadian Urological Association and also serves as chair of the Canadian Urological Oncology Group. He has authored over 280 peer-reviewed manuscripts and has been particularly active in the development of clinical guidelines and national and international collaborations in kidney, bladder, and prostate cancer.
Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and a GI medical oncologist at BC Cancer in Vancouver, Canada. Dr. Gill serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee and as the President of the Canadian Association of Medical Oncologists
Dr. Heng is the Division Head of Medical Oncology at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and trained at the BC Cancer Agency and Cleveland Clinic Taussig Cancer Institute. He has a Masters of Public Health from Harvard University and has a keen interest in outcomes, prognostic factors and clinical trials research in kidney, bladder, prostate and testicular cancers.
Dr. Juergens completed a fellowship in medical oncology with a focus on thoracic malignancies at the Johns Hopkins Medical Institute. Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University in 2011.
Dr. Juergens’ clinical expertise is in lung cancer. Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials. Her passion is expanding knowledge and access to clinical trials. She is a member of the Early Therapy Advisory Committee and member of the Lung Disease Site Group Executive in the Canadian Cancer Trials Group.
She chaired the Lung Cancer Disease Site Team at the Juravinski Cancer Centre from 2013-2024. She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre. She is a member of the Escarpment Cancer Research Institute and the Centre for Discovery and Cancer Research at McMaster University. She is a proud teacher and mentor and winner of the 2024 Women in Cancer Mentor of the Year. She is also a patient advocate and serves as the Medical Advisory Committee Chair for Lung Cancer Canada. Her efforts were acknowledged by the 2024 Canadian Association of Medical Oncologists Humanitarian Award.
Dr. Sacher is a Thoracic Oncologist & Affiliate Scientist at the Princess Margaret Cancer Centre and an Assistant Professor in the Departments of Medicine & Immunology at the University of Toronto. Dr. Sacher completed his medical degree at the University of Toronto and residency at the Toronto General Hospital and Princess Margaret Cancer Center. He has subsequently completed a research fellowship in thoracic oncology at the Dana-Farber Cancer Institute and holds a Master’s degree in clinical trial design, genomics and drug development from Harvard Medical School. He has previously served as an Assistant Professor of Medicine and Attending Thoracic Oncologist at Columbia University & New York-Presbyterian Hospital. He has been awarded an American Society of Clinical Oncology (ASCO) Career Development Award (CDA) and Canadian Institutes for Health Research (CIHR) Project Grant for his work on tumor immunotherapy.
